New Era of Regenerative Medicine Transformation, Starry Moon Biology Debuts at TERMIS-AP 2025

From October 16th to 19th, 2025, with the theme of "Translating Regenerative Medicine into a New Era", the "TERMIS-AP 2025" International Society for Organizational Engineering and Regenerative Medicine Asia Pacific Conference was grandly held in Wuhan. As a top academic event that radiates globally and focuses on the Asia Pacific region, this conference focuses on cutting-edge achievements and clinical translation in interdisciplinary fields such as biomaterials, tissue engineering, stem cells, and regenerative medicine. It attracts over 1600 experts, scholars, industry leaders, regulatory representatives, and others from more than 30 countries and regions around the world to gather and discuss a new chapter in the innovative development of regenerative medicine.

At the invitation of the organizing committee of the conference, Researcher Xu Liming from the China National Institute for Food and Drug Control and Researcher Masanori Kikuchi from the National Institute of Materials Science in Japan presided over a special topic titled "International Standard Development in TERM Field". They systematically shared the development status of ISO/TC150/SC1 and ISO/TC150/SC7 in the field of tissue engineering and regenerative medicine, as well as ISO/TC 276 in the development of international standards related to biomaterials, the importance and necessity of promoting relevant international standards, and how to participate in international standardization work. At the meeting, Ryuske Nakaoka, Manager of ISO/TC150/SC7 (National Institute of Health Sciences, Japan), Masanori Kikuch, Convenor of ISO/TC150/SC71/WG3, and Researcher Xu Liming respectively introduced ISO/TC150/SC7 and ISO/TC150/SC1, as well as the standardization work overview of ISO/TC276, the international standard development process, and the current status of standardization related to tissue engineering regenerative medicine. Researcher Zhang Guifeng from the Institute of Process Engineering of the Chinese Academy of Sciences shared the progress related to the development and standardization of collagen detection methods (ISO/FDIS 6631), and Dr. Cheng Shiyu from Roumai Medical (Shenzhen) Co., Ltd. made a report on the industrialization of human collagen based on tissue engineering technology and the research and development of standard substances.

At the meeting, Dr. Zhao Hongshi, General Manager and Chief Scientist of Zhejiang Xingyue Biotechnology Co., Ltd., gave a report entitled "Standard development on silk fibroin materials", detailing the development history and current situation of silk fibroin materials in China and even the world, sharing the domestic and international construction status of silk fibroin material standards, and conveying the "Chinese experience" that meets international collaborative needs to the world. During the communication session, Dr. Zhao Hongshi also had in-depth exchanges with experts, scholars, and industry representatives from countries such as the United States, Australia, and the Netherlands on key issues such as the standardization of silk fibroin technology standards and regional collaborative applications.

As a pioneer in the medical application of silk fibroin in China, Xingyue Biotechnology actively responds to the national call and participates in promoting the development of domestic and international standards. At the same time, the company's experience in promoting the transformation of silk fibroin research achievements into practical products reflects the mission of Chinese enterprises to actively take on the role of "standard practice pioneers" in the field of high-end biomaterials. This practice provides important support for the country to seize the high ground of global technological competition and demonstrates the strategic determination of enterprises.